Drug Patent Watch

OCTOBER 12, 2021

International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions. This paper was originally published by Md.

Production 105

Production Pharmaceuticals Licensing Licensing 105

Drug Discovery World

JULY 13, 2023

Recursion, a clinical stage company decoding biology to industrialise drug discovery, has announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE).

Drugs 130

Drugs Pharmaceutical Companies Licensing Licensing 130

Drug Discovery World

AUGUST 1, 2023

Synthetic biology is increasingly important to drug discovery and development. Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Drugs 130

Drugs Licensing Licensing Engineering 130

Drug Discovery World

MAY 6, 2024

In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. In 2022, the continent held a 22.4% In 2022, the continent held a 22.4%

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

Drug Discovery World

MARCH 27, 2023

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Ono will have an exclusive option to license global rights to the candidates for further development and commercialisation.

Licensing 130

Licensing Licensing Drugs Pharmaceuticals 130

Drug Discovery World

FEBRUARY 27, 2023

Under a new agreement, Destiny Pharma and Sebela Pharmaceuticals will co-develop NTCD-M3, Destiny’s lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence. The post Companies agree up to $570m deal for C difficile drug appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

The Pharma Data

OCTOBER 27, 2021

Teva Pharmaceutical Industries Ltd. NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Teva Pharmaceutical Industries Ltd. About Teva.

Licensing 52

Licensing Licensing Disease Small Molecule 52

Drug Discovery World

JULY 2, 2024

This article will examine the regional focus of the country’s life sciences industry, its infrastructure of bioparks, and how this foundation ensures Switzerland maintains its role as a global leader in drug discovery. Switzerland, however, boasts three (or arguably, four) separate yet complimentary centres of life science innovation.

Science 147

Science Drugs Clinical Trials Licensing 147

Drug Discovery World

SEPTEMBER 26, 2022

DDW Editor Reece Armstrong explores the rise of drug repurposing and the benefits and disadvantages it brings to drug discovery and development. . Drug repurposing, the act of finding new clinical targets for both approved and unapproved drugs, has emerged as a viable alternative to traditional drug discovery approaches. .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Drug Discovery World

FEBRUARY 19, 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. antibody-drug conjugate [ADC] pipelines in some oncology settings).

Drug Development 147

Drug Development Small Molecule Drugs Therapies 147

Drug Discovery World

SEPTEMBER 22, 2022

Pfizer has extended its multi-year partnership with CytoReason to use CytoReason’s artificial intelligence (AI) technology for Pfizer’s drug development programs. . Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support.

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Licensing Licensing 130

FDA Law Blog: Biosimilars

JANUARY 11, 2024

(HPM) Directors, Karla Palmer and Dara Levy , will present at the Puerto Rico Pharmaceutical Summit 2024, February 6, 2024, at the La Concha Renaissance San Juan Resort in San Juan, Puerto Rico.

Pharmaceuticals 59

Pharmaceuticals Compliance Licensing Licensing 59

Drug Discovery World

JULY 18, 2024

The UK has the potential to become the global leader in pharmaceutical cannabinoid R&D, according to a new report published by the Cannabinoid Research and Development Group (CRDG). The report argues that pharmaceutical cannabinoid R&D is in danger of being held back in the UK by “inappropriately excessive” regulation.

Science 130

Science Government Pharmaceuticals Regulations 130

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Pharmaceuticals Pharmaceutical Companies 40

DrugBank

AUGUST 15, 2024

Drug development is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. UCSD, with its world-renowned Center for Microbiome Innovation , provides expertise in microbial genomics and drug discovery platforms.

Drug Development 82

Drug Development Clinical Trials Drugs Therapies 82

Drug Channels

OCTOBER 11, 2022

I am pleased to announce our new 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: U.S.

Pharmaceuticals 74

Pharmaceuticals Biosimilars Licensing Licensing 74

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Therapies Pharmaceutical Companies 52

Drug Discovery World

MARCH 28, 2024

Both Teva and Daichi Sankyo have been found to be in breach of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice by the Prescription Medicines Code of Practice Authority (PMCPA). The post Teva and Daiichi Sankyo found in breach of the UK ABPI Code appeared first on Drug Discovery World (DDW).

Licensing 130

Licensing Licensing Pharmaceuticals Therapies 130

FDA Law Blog: Biosimilars

JUNE 17, 2024

Claud — FDA’s Office of Pharmaceutical Quality (OPQ) in the Center for Drug Evaluation and Research (CDER) is charged with assuring that drugs marketed in the U.S. Last week, OPQ released its 6th Annual Report on the State of Pharmaceutical Quality. By Kalie E. Richardson & John W.M.

Pharmaceuticals 59

Pharmaceuticals FDA Production Licensing 59

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

OCTOBER 2, 2023

INAQOVI, developed by Otsuka Pharmaceutical and Astex Pharmaceuticals, is the first oral hypomethylating agent to be licensed in the EEA in this patient population. The post European Commission approves oral treatment for leukaemia appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Pharmacokinetics Clinical Trials Licensing 130

The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

Drug Discovery World

SEPTEMBER 14, 2023

As the second quarter of 2023 draws to a close, DDW’s Megan Thomas reviews key updates and results from three top pharmaceutical companies. In July 2023, AstraZeneca and Ionis Pharmaceuticals expanded their existing collaboration on eplontersen to also include Latin America. billion, a decrease of $15.0

Vaccine 147

Vaccine FDA Approval Drugs Licensing 147

Drug Channels

OCTOBER 5, 2021

I am pleased to announce our new 2021–22 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. Twice a year, I spend my evenings and weekends writing two comprehensive, fact-based, and nonpartisan reports on drug channel economics.

Pharmaceuticals 75

Pharmaceuticals Biosimilars Licensing Licensing 75

Drug Discovery World

OCTOBER 4, 2023

The US Food and Drug Administration (FDA) has accepted Rocket Pharmaceuticals’ Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene autotemcel). The post FDA acceptance advances investigational gene therapy appeared first on Drug Discovery World (DDW).

FDA 130

FDA Therapies Pharmaceuticals Licensing 130

Drug Discovery World

OCTOBER 21, 2022

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. billion, plus royalties on net sales.

Licensing 130

Licensing Licensing Treatment Pharmaceuticals 130

The Pharma Data

JANUARY 6, 2021

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. Working with leading pharmaceutical companies such as Pfizer, will help us achieve our goal.”

Licensing 52

Licensing Licensing Clinical Trials Pharmaceutical Companies 52

Drug Channels

OCTOBER 10, 2023

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. Click here to download a free report overview (including a summary of industry trends, the Table of Contents, and a List of Exhibits) New Drug Channels Institute Study: U.S.

Pharmaceuticals 40

Pharmaceuticals Specialty Pharmacies Pharmacy Biosimilars 40

Collaborative Drug

JUNE 21, 2024

Burlingame, CA, June 21, 2024 — Collaborative Drug Discovery (CDD), a leading provider of data management solutions for the pharmaceutical and biotechnology industries, is pleased to announce the integration of iChemLabs' industry-leading IUPAC naming technologies into CDD Vault.

Licensing 59

Licensing Licensing Pharmaceuticals Drugs 59

The Pharma Data

DECEMBER 16, 2020

–( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc. NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical Co., 17, 2020 09:00 UTC.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

The Pharma Data

JULY 18, 2021

Food and Drug Administration (FDA) granted Priority Review designation for the Biologics License Application (BLA) for their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in January 2022. Source link: [link].

Licensing 52

Licensing Licensing Vaccine FDA 52

Drug Discovery World

SEPTEMBER 21, 2022

Otsuka Pharmaceutical’s Lupkynis (voclosporin) is the first oral treatment to be approved in Europe for the treatment of active lupus nephritis (LN) in adult patients. The combination treatment for this indication was approved by the US Food and Drug Administration in 2021 and gained a positive opinion from the CHMP earlier this year.

Treatment 130

Treatment Licensing Licensing Pharmaceuticals 130

Drug Patent Watch

JULY 13, 2020

Mudawi in the Journal of Pharmaceutical Research International under the terms of the Creative Commons Attribution License.…. The post Common Drugs with Effective Off-Label Uses appeared first on DrugPatentWatch - Make Better Decisions. This article was originally published by Mohammed M. Alshehri and Mahmoud M.

Licensing 94

Licensing Licensing International Drugs 94

Drug Discovery World

JULY 2, 2024

City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use of CBM588 to enhance the efficacy of checkpoint inhibitors used to treat cancer, including metastatic renal cell carcinoma. Scientists from Osel and Miyarisan Pharmaceutical, the manufacturer of CBM588, collaborated on the study.

Trials 147

Trials Treatment Clinical Trials Licensing 147

FDA Law Blog: Biosimilars

JANUARY 3, 2024

Responsible for “Protecting Human and Animal Health,” CVM makes sure that the drugs, devices, and food we provide for our pets are safe and effective. CVM does not regulate the practice of veterinary medicine (that’s a state licensing board) or vaccines for animal diseases (that’s USDA).

Drugs 59

Drugs FDA Licensing Licensing 59

Drug Discovery World

JANUARY 10, 2024

AIO-001 was exclusively licensed to Aiolos outside of Greater China by Jiangsu Hengrui Pharmaceuticals. The post GSK expands respiratory pipeline with Aiolos Bio acquisition appeared first on Drug Discovery World (DDW).

Pharmacokinetics 130

Pharmacokinetics Licensing Licensing Clinical Development 130

BioPharma Drive: Drug Pricing

OCTOBER 20, 2023

The deal is worth up to $22 billion in total, making it one of the largest pharmaceutical licensing agreements by value.

Licensing 62

Licensing Licensing Pharmaceuticals Drugs 62